Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the focus of research over the next 5 years to improve prediction in smoldering myeloma. There will be developments in genomic, microenvironmental and epigenetic factors to add to the arsenal of clinical factors. Dynamic factors will also need to be further understood to more accurately describe the progression of the disease. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.